Statistics for Halozyme Therapeutics (id:7369 HALO)

Valuation metrics

Market cap

5.42B

Enterprise value

6.68B

Trailing P/E (ttm)

14.10

Forward P/E

8.80

PEG ratio

8.80

Price/Sales (ttm)

5.72

Price/Book (mrq)

11.96

Enterprise Value/Revenue

7.05

Enterprise Value/EBITDA

12.07

Overview

Shares outstanding

127.23M

Float

125.89M

Shares short

10.25M

% Held by insiders

0.01%

% Held by institutions

1.00%

Average volume (10 days)

2.43M

Average volume (90 days)

Price summary

52-Week low

33.15

52-Week high

65.53

52-Week change

16.63%

Beta

1.29

50-Day moving average

56.04

200-Day moving average

49.02

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

41.43%

Operating margin

56.26%

Operational effectiveness

Return on assets

14.87%

Return on equity

111.83%

Income statement

Revenue (ttm)

7.43

Revenue per share (ttm)

7.43

Quarterly revenue growth (yoy)

0.67

Gross profit (ttm)

636.89M

EBITDA

558.60M

Net income to common (ttm)

392.47M

Diluted EPS (ttm)

3.02

Quarterly earnings growth (yoy)

67.40%

Balance sheet

Total cash (mrq)

666.31M

Total cash per share (mrq)

5.24

Total debt (mrq)

1.53B

Total Debt/Equity (mrq)

339.05

Current ratio (mrq)

1.04K%

Book value per share (mrq)

3.56

Cash flow

Cash flow statement

402.95M

Levered free cash flow (LFCF)

339.29M